<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hypercoagulability in nephrotic syndrome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hypercoagulability in nephrotic syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hypercoagulability in nephrotic syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jai Radhakrishnan, MD, MS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Brad H Rovin, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Patients with the nephrotic syndrome (proteinuria greater than 3.5 g/day and hypoalbuminemia [less than 3 g/dL]) are at increased risk for venous thrombosis, particularly deep vein thrombosis (DVT) and renal vein thrombosis (RVT) [<a href="#rid1">1-4</a>]. Pulmonary embolization (mostly asymptomatic) is relatively common, and there are case reports of cerebral venous thrombosis [<a href="#rid1">1-4</a>]. Arterial thromboses (eg, limb and cerebral) also occur with higher frequency than in the general population [<a href="#rid4">4-7</a>].</p><p>This topic will review the epidemiology and pathogenesis of hypercoagulability in the nephrotic syndrome and the prevention of thromboembolism in patients with nephrotic syndrome. Overviews of the nephrotic syndrome and causes of venous thrombosis as well as the treatment of venous thrombosis are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3084.html" rel="external">"Overview of heavy proteinuria and the nephrotic syndrome"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/95336.html" rel="external">"Venous thromboembolism: Initiation of anticoagulation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/95395.html" rel="external">"Venous thromboembolism: Anticoagulation after initial management"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The incidence of both venous and arterial thrombosis is higher in patients with nephrotic syndrome compared with estimates in the general population [<a href="#rid7">7,8</a>]. In a Danish registry study of 3967 adults with first-time nephrotic syndrome, the one-year absolute risks of arterial and venous thromboembolism were 4 and 3 percent, respectively, and the 10-year absolute risks were 14 and 8 percent, respectively [<a href="#rid8">8</a>]. By comparison, among age- and sex-matched controls, the one-year risks of arterial and venous thromboembolism were 1 and 0.4 percent, respectively, and 10-year risks were 9 and 3 percent, respectively. Among patients with the nephrotic syndrome, the highest 10-year risks were observed with ischemic stroke (8 percent) and myocardial infarction (6 percent). </p><p>The risk of venous thromboembolism among patients with other forms of kidney disease appears to be lower than that for patients with nephrotic syndrome but is higher than that for patients without kidney disease. In another Danish registry study that evaluated the risk of thromboembolism among patients with and without kidney disease, the adjusted odds ratio (OR) for venous thromboembolism was 1.41 (95% CI 1.22-1.63) for patients with hypertensive nephropathy, 1.46 (95% CI 1.30-1.64) for those with diabetic nephropathy, 1.48 (95% CI 1.22-1.81) for those with polycystic kidney disease, 2.03 (95% CI 1.76-2.34) for those with glomerulonephritis without nephrotic syndrome, and 2.89 (95% CI 2.26-3.69) for those with nephrotic syndrome [<a href="#rid9">9</a>]. The risk for thromboembolism was most pronounced within the first three months after the diagnosis of kidney disease (adjusted OR 23.23 and 8.64 for nephrotic syndrome and glomerulonephritis, respectively) and decreased thereafter; however, the risk remained elevated even at five years after the diagnosis.</p><p>An increase in thromboembolic risk is also present in children with the nephrotic syndrome. (See  <a class="medical medical_review" href="/d/html/6102.html" rel="external">"Complications of nephrotic syndrome in children", section on 'Thromboembolism'</a>.)</p><p class="headingAnchor" id="H131332569"><span class="h2">Risk factors for thromboembolism</span><span class="headingEndMark"> — </span>The risk of thrombosis varies among the causes of nephrotic syndrome and appears to be highest in patients with membranous nephropathy [<a href="#rid4">4,8,10-13</a>]. This was illustrated in a cohort of 1313 patients with idiopathic glomerular disease due to membranous nephropathy, focal segmental glomerulosclerosis, or immunoglobulin A (IgA) nephropathy [<a href="#rid10">10</a>]. The incidence of venous thromboembolic events was much higher in membranous nephropathy (7.9 percent) and focal segmental glomerulosclerosis (3.0 percent) than in IgA nephropathy (0.4 percent). The histologic diagnosis remained a predictive factor for thrombosis after adjustment for the degree of proteinuria (which was much higher at presentation in membranous nephropathy and focal segmental glomerulosclerosis [median 5.6 and 3.7 versus 1.6 g/day in IgA nephropathy]) and the serum albumin concentration.</p><p>Patients with membranous nephropathy associated with lupus also appear to be at high risk for thromboembolism. In a study of 66 such patients, venous thromboembolism occurred in 15 (23 percent) at a mean follow-up of 6.9 years [<a href="#rid14">14</a>]. Factors other than nephrotic syndrome can contribute to an increased incidence of thromboembolism in patients with lupus, such as antiphospholipid antibodies. (See  <a class="medical medical_review" href="/d/html/3093.html" rel="external">"Lupus nephritis: Therapy of lupus membranous nephropathy", section on 'General supportive measures in all patients'</a>.)</p><p>An increased risk of thromboembolism has also been reported in patients with minimal change disease [<a href="#rid15">15,16</a>]. As an example, a large case series of 125 patients diagnosed with minimal change disease in adulthood or late adolescence found that arterial or venous thrombosis occurred in 11 (9 percent) [<a href="#rid15">15</a>].</p><p>In addition to the cause of nephrotic syndrome, the risk of thrombosis is also related to the severity of hypoalbuminemia and tends to occur early in the course of the disease [<a href="#rid4">4,7,11,12,17-19</a>]. This is particularly true in membranous nephropathy as illustrated in a report of 898 patients with this disorder in the Glomerular Disease Collaborative Network and the Toronto Glomerulonephritis Registry [<a href="#rid11">11</a>]. Mean proteinuria was 7.7 g/day, and the mean serum albumin was 2.6 g/dL (26 g/L).</p><p>The following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>Clinically evident and radiologically confirmed venous thromboembolic events occurred in 7.2 percent of patients, which is similar to the 7.9 percent incidence in the study cited above [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The median time to the first thromboembolic event was 3.8 months; 74 percent occurred within the first two years of diagnosis, and 86 percent occurred within three years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A low serum albumin concentration at the time of diagnosis, but not the degree of proteinuria, independently predicted a venous thromboembolic event. Compared with patients who had a serum albumin concentration greater than 2.8 g/dL (28 g/L), the risk of an event was significantly higher in patients with a serum albumin concentration ≤2.8 g/dL (28 g/L)—9.4 versus 3.2 percent, adjusted relative risk 2.5. The risk increased by approximately twofold for every 1 g/dL (10 g/L) reduction in serum albumin below this threshold. The duration of hypoalbuminemia (less than or more than six months) was not an independent risk factor for venous thromboembolism.</p><p></p><p>To assess the absolute risks of venous and arterial thromboembolism, 298 patients with nephrotic syndrome due to primary glomerular disease (minimal change disease, membranous nephropathy, focal segmental glomerulosclerosis, membranoproliferative glomerulonephritis), diabetic nephropathy, or not otherwise specified were followed for a mean of 10±9 years [<a href="#rid7">7</a>]. The annual incidences of venous thromboembolism and arterial thromboembolism were 1.0 and 1.5 percent, respectively, with the highest incidences occurring during the first six months of follow-up (9.9 and 5.5 percent, respectively).</p><p>In other causes of the nephrotic syndrome, which are associated with a lower risk of thromboembolism, the risk is particularly increased at a lower serum albumin (below 2.0 g/dL [20 g/L]) in some [<a href="#rid17">17-19</a>] but not all studies [<a href="#rid4">4,12</a>]. In general, low serum albumin levels are a surrogate biomarker for thrombophilia in patients with nephrotic syndrome. It is important to note that serum albumin levels measured by bromocresol green methods may overestimate the serum albumin concentration compared with other methods such as bromocresol purple or immunonephelometry [<a href="#rid20">20</a>].</p><p>The possible role of prophylactic anticoagulation in patients with nephrotic syndrome who are at increased risk for thromboembolism is discussed below. (See <a class="local">'Prevention of thromboembolism'</a> below.)</p><p class="headingAnchor" id="H4"><span class="h2">Deep vein thrombosis</span><span class="headingEndMark"> — </span>Deep vein thrombosis (DVT) of the extremities is the most commonly observed thromboembolic event in patients with nephrotic syndrome [<a href="#rid21">21,22</a>]. This was illustrated in a review of discharge diagnoses from hospitals in the United States from 1979 to 2005 in which 925,000 patients had a diagnosis of nephrotic syndrome [<a href="#rid21">21</a>]. Among the nephrotic patients, 14,000 (1.5 percent) were diagnosed with DVT while fewer than 5000 had renal vein thrombosis (RVT). The relative risk of DVT was significantly increased (1.72) in nephrotic compared with nonnephrotic patients.</p><p class="headingAnchor" id="H5"><span class="h2">Pulmonary embolism</span><span class="headingEndMark"> — </span>Pulmonary embolism (PE) has been described in nephrotic patients with or without an evident DVT or RVT [<a href="#rid1">1,4,12,13,17,18,23-25</a>]. The estimated prevalence of asymptomatic PE in patients with the nephrotic syndrome ranges from 12 to over 30 percent, as illustrated in the following findings:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 151 consecutive nephrotic patients, 94 underwent ventilation-perfusion lung scan (V/Q scan) [<a href="#rid12">12</a>]. PE was present in 12 patients (13 percent): Five had a PE associated with chronic or acute RVT, and seven had an isolated PE.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a series of 89 nephrotic patients with a serum albumin concentration &lt;2.0 g/dL (20 g/L), 19 (21 percent) had a high-probability V/Q scan and, in an additional 25 patients with low or intermediate probability scans, arteriography demonstrated PE in 10 (40 percent) [<a href="#rid17">17</a>].</p><p></p><p>The risk of symptomatic PE also appears to be increased. In the review cited above of discharge diagnoses from hospitals in the United States, there was a 39 percent increase in PE in nephrotic compared with nonnephrotic patients [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H1033152863"><span class="h2">Renal vein thrombosis</span><span class="headingEndMark"> — </span>The epidemiology of RVT is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/119627.html" rel="external">"Renal vein thrombosis in adults", section on 'Epidemiology'</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The cause of the hypercoagulable state in patients with nephrotic syndrome is not well understood. Studies evaluating measures of hemostasis activation, such as the plasma level of fibrinopeptide A, which is cleaved from fibrinogen by thrombin, suggest that even asymptomatic nephrotic patients have evidence of ongoing subclinical coagulation [<a href="#rid26">26</a>]. A variety of hemostatic abnormalities have been described, including decreased levels of natural anticoagulants such as plasminogen and protein C and S (due to urinary losses); increased platelet activation; hyperfibrinogenemia; inhibition of plasminogen activation; and the presence of high-molecular-weight fibrinogen moieties in the circulation [<a href="#rid2">2,4,27-31</a>]. Although previous studies suggested that urinary loss of antithrombin III leading to acquired antithrombin deficiency was a potentially important contributing mechanism, an analysis of three independent cohorts of patients with nephrotic syndrome found an inconsistent relationship between antithrombin levels and hypercoagulopathy in nephrotic patients [<a href="#rid32">32</a>].</p><p>The tendency to form thrombi at the renal vein in the nephrotic syndrome may be due in part to the loss of fluid across the glomerulus [<a href="#rid4">4</a>]. The ensuing hemoconcentration in the postglomerular circulation, which is worsened by diuretic therapy, may promote thrombus formation in patients who are already hypercoagulable.</p><p class="headingAnchor" id="H122129333"><span class="h1">PREVENTION OF THROMBOEMBOLISM</span><span class="headingEndMark"> — </span>The likelihood of benefit from prophylactic anticoagulation is dependent upon three factors: the incidence of thrombotic events, the ability of anticoagulation to prevent such events, and the bleeding risk associated with anticoagulation. (See <a class="local">'Risk factors for thromboembolism'</a> above and  <a class="medical medical_review" href="/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects", section on 'Complications'</a>.)</p><p>No randomized controlled trials have compared the risks associated with undiagnosed venous thrombosis with the risk of long-term anticoagulation in patients with nephrotic syndrome. In a prospective, uncontrolled study, 30 patients with nephrotic syndrome (14 with membranous nephropathy, 13 with focal segmental glomerulosclerosis, median serum albumin 1.7 g/dL [17 g/L], and median protein excretion of 9 g/day) were treated with low-molecular-weight heparin for a median of 13 months [<a href="#rid33">33</a>]. Patients with a serum creatinine &gt;2.3 mg/dL (203 micromol/L) and those who weighed less than 40 kg received one-half the typical prophylactic dose of low-molecular-weight heparin. At baseline, patients had no thromboses, as assessed by Doppler ultrasound of the renal and lower extremity veins and ventilation-perfusion scan (V/Q scan) of the lungs, and reassessment every three months demonstrated no thromboses throughout follow-up. No serious adverse events were reported. Given the small number of patients in this study, however, these findings are insufficient to firmly establish the efficacy of low-molecular-weight heparin in preventing thromboembolism in this patient population.</p><p>Because of the lack of randomized trials, the optimal approach to prophylactic anticoagulation in patients with nephrotic syndrome is not well defined. Furthermore, it is unclear if the findings in membranous nephropathy apply to other causes of nephrotic syndrome, since membranous nephropathy is associated with the highest risk of thromboembolic events and similar large series are not available for the other causes. (See <a class="local">'Risk factors for thromboembolism'</a> above.)</p><p class="headingAnchor" id="H470876705"><span class="h2">Approach to prophylactic anticoagulation</span><span class="headingEndMark"> — </span>In general, the risk of thrombosis is inversely related to the serum albumin levels. In particular, patients with membranous nephropathy who have very low serum albumin levels and a low to intermediate risk of serious bleeding may benefit from prophylactic anticoagulation [<a href="#rid34">34-36</a>]. In addition, pregnant patients with nephrotic syndrome, regardless of cause, are at increased risk for venous thromboembolism and may also benefit from prophylactic anticoagulation. Our approach to prophylactic anticoagulation is discussed below (<a class="graphic graphic_algorithm graphicRef121272" href="/d/graphic/121272.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H2220080883"><span class="h3">Assessment of bleeding risk</span><span class="headingEndMark"> — </span>In all patients with nephrotic syndrome who do not have a contraindication to anticoagulation (<a class="graphic graphic_table graphicRef107527" href="/d/graphic/107527.html" rel="external">table 1</a>), the decision to prescribe prophylactic anticoagulation must be balanced against the risk of bleeding. When the risk of anticoagulation-associated bleeding is unclear, it can be estimated using various prediction models, including the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) risk score [<a href="#rid37">37</a>] or the HAS-BLED bleeding risk score (<a class="calc calc_professional" href="/d/html/94104.html" rel="external">calculator 1</a>). (See  <a class="medical medical_review" href="/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR", section on 'Mitigating bleeding risk'</a> and  <a class="medical medical_review" href="/d/html/119889.html" rel="external">"Risks and prevention of bleeding with oral anticoagulants", section on 'Bleeding risk scores'</a>.)</p><p>In general, prophylactic anticoagulation should be <strong>avoided</strong> in patients who are considered to be at high risk for bleeding.</p><p class="headingAnchor" id="H3054563122"><span class="h3">Patients with membranous nephropathy</span><span class="headingEndMark"> — </span>As discussed above, patients with membranous nephropathy are at high risk for thromboembolism. Patients who have very low serum albumin levels and a low to intermediate risk of serious bleeding may benefit from prophylactic anticoagulation, even if there are no other reasons for anticoagulation [<a href="#rid34">34-36</a>]. In addition, the presence of other risk factors for thromboembolism may also impact the clinical decision to initiate prophylactic anticoagulation. (See <a class="local">'Risk factors for thromboembolism'</a> above and  <a class="medical medical_review" href="/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis"</a>.)</p><p>In nonpregnant patients with membranous nephropathy, our approach to prophylactic anticoagulation is based upon the assessed bleeding risk (see <a class="local">'Assessment of bleeding risk'</a> above) and the serum albumin concentration (<a class="graphic graphic_algorithm graphicRef121272" href="/d/graphic/121272.html" rel="external">algorithm 1</a>). There is no high-quality evidence to support these (or any other) serum albumin thresholds, and these thresholds are largely based upon data from existing observational studies [<a href="#rid35">35,38</a>] as well as our clinical experience:</p><p class="bulletIndent1"><span class="glyph">●</span>If the anticoagulation-associated bleeding risk is high <strong>or </strong>the serum albumin level is ≥3.0 g/dL, we do <strong>not</strong> administer prophylactic anticoagulation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the anticoagulation-associated bleeding risk is low <strong>and </strong>the serum albumin level is &lt;3.0 g/dL, we administer prophylactic anticoagulation with low-molecular-weight heparin or <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the anticoagulation-associated bleeding risk is intermediate <strong>and </strong>the serum albumin level is &lt;2.0 g/dL, we administer prophylactic anticoagulation with low-molecular-weight heparin or <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the anticoagulation-associated bleeding risk is intermediate <strong>and</strong> the serum albumin level is between 2.0 and 2.9 g/dL, the decision to administer prophylactic anticoagulation should be made on a case-by-case basis after weighing the benefits and risks of anticoagulation. There are insufficient data in this patient population to support a particular therapeutic approach. Some contributors to this topic would administer prophylactic antiplatelet therapy with <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> (81 mg once daily). Other contributors would administer low-molecular-weight heparin or <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> when the serum albumin is between 2.0 and 2.5 g/dL and would not administer prophylactic anticoagulation when the serum albumin is between 2.6 and 2.9 g/dL.</p><p></p><p>The dosing and duration of prophylactic anticoagulation are discussed elsewhere in this topic. (See <a class="local">'Dosing and efficacy'</a> below and <a class="local">'Duration of therapy'</a> below.)</p><p>We do not routinely prescribe direct oral anticoagulants (DOACs) as prophylactic anticoagulation in patients with membranous nephropathy, given the limited data evaluating their use in this patient population. The use of DOACs may be considered in patients with side effects or inadequate therapeutic effects from <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> and if the patient is unwilling to take low-molecular-weight heparin [<a href="#rid39">39</a>]. However, in one case report, a patient with membranous nephropathy developed recurrent venous thromboembolism while receiving therapeutic dosing of the oral factor Xa inhibitor <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a> [<a href="#rid40">40</a>], highlighting the need for additional studies in this high-risk patient population. (See  <a class="medical medical_review" href="/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"</a>.)</p><p class="headingAnchor" id="H3403624996"><span class="h3">Patients with other causes of nephrotic syndrome</span><span class="headingEndMark"> — </span>In nonpregnant patients with a cause of nephrotic syndrome other than membranous nephropathy (eg, minimal change disease, focal segmental glomerulosclerosis), our approach to prophylactic anticoagulation is based upon the assessed bleeding risk (see <a class="local">'Assessment of bleeding risk'</a> above) and the serum albumin concentration (<a class="graphic graphic_algorithm graphicRef121272" href="/d/graphic/121272.html" rel="external">algorithm 1</a>). As with membranous nephropathy, there is no high-quality evidence to support these (or any other) serum albumin thresholds, and these thresholds are largely based upon data from existing observational studies [<a href="#rid38">38</a>] as well as our clinical experience:</p><p class="bulletIndent1"><span class="glyph">●</span>If the anticoagulation-associated bleeding risk is high (see <a class="local">'Assessment of bleeding risk'</a> above) <strong>or </strong>the serum albumin level is ≥3.0 g/dL, we do <strong>not</strong> administer prophylactic anticoagulation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the anticoagulation-associated bleeding risk is low or intermediate <strong>and </strong>the serum albumin level is &lt;2.0 g/dL, we administer low-molecular-weight heparin or <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the anticoagulation-associated bleeding risk is low or intermediate <strong>and </strong>the serum albumin level is between 2.0 and 2.9 g/dL, the decision to administer prophylactic anticoagulation should be made on a case-by-case basis. Some contributors to this topic would administer prophylactic antiplatelet therapy with <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> (81 mg once daily). One contributor would administer low-molecular-weight heparin or <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> in patients with acute, severe nephrotic syndrome due to minimal change disease, given the higher risk of venous thromboembolism in such patients. (See <a class="local">'Risk factors for thromboembolism'</a> above.)</p><p></p><p>The dosing and duration of prophylactic anticoagulation are discussed elsewhere in this topic. (See <a class="local">'Dosing and efficacy'</a> below and <a class="local">'Duration of therapy'</a> below.)</p><p>We do not routinely prescribe DOACs as prophylactic anticoagulation in patients with a cause of nephrotic syndrome other than membranous nephropathy, given the limited data evaluating their use in this patient population. However, use of DOACs may be considered in patients with side effects or inadequate therapeutic effects from <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> and if the patient is unwilling to take low-molecular-weight heparin [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"</a>.)</p><p class="headingAnchor" id="H3596887148"><span class="h3">Pregnant patients</span><span class="headingEndMark"> — </span>Our approach to prophylactic anticoagulation in pregnant women with nephrotic syndrome is similar to that for nonpregnant patients with nephrotic syndrome, which is based upon the assessed bleeding risk and the serum albumin concentration (see <a class="local">'Assessment of bleeding risk'</a> above and <a class="local">'Patients with membranous nephropathy'</a> above and <a class="local">'Patients with other causes of nephrotic syndrome'</a> above). However, since pregnancy is a prothrombotic state, we have a lower threshold for administering prophylactic anticoagulation to prevent venous thromboembolism. There are no studies that have evaluated the benefits or risks of prophylactic anticoagulation in pregnant women with nephrotic syndrome, and our approach is based primarily upon clinical experience:</p><p class="bulletIndent1"><span class="glyph">●</span>If the anticoagulation-associated bleeding risk is high (see <a class="local">'Assessment of bleeding risk'</a> above) <strong>or </strong>the serum albumin level is ≥3.0 g/dL, we <strong>do not</strong> administer prophylactic anticoagulation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Regardless of the cause of nephrotic syndrome, if the anticoagulation-associated bleeding risk is low or intermediate <strong>and </strong>the serum albumin level is &lt;2.5 g/dL, we administer low-molecular-weight heparin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the patient has membranous nephropathy, the anticoagulation-associated bleeding risk is low, <strong>and </strong>the serum albumin is &lt;3.0 g/dL, we administer low-molecular-weight heparin.</p><p></p><p>Low-molecular-weight heparin or <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a> is appropriate for prophylactic anticoagulation in pregnancy. <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> should be avoided because it crosses the placenta and can have adverse fetal effects, but can be used postpartum, even in breastfeeding women. DOACs should be avoided during pregnancy and should not be given to women who are breastfeeding. Dosing of anticoagulation and other issues related to the use of anticoagulants during pregnancy and postpartum are discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum"</a>.)</p><p class="headingAnchor" id="H2859296682"><span class="h2">Dosing and efficacy</span><span class="headingEndMark"> — </span>Initial dosing of low-molecular-weight heparin and <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> for prophylactic anticoagulation in patients with nephrotic syndrome is the same as that used to treat venous thromboembolism in the general population. Low-molecular-weight heparin should be used with caution in individuals whose kidney function is markedly reduced and/or unstable. If used (particularly for a long duration), intermittent monitoring of anti-factor Xa is advised [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Monitoring heparins'</a> and  <a class="medical medical_review" href="/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects", section on 'Dosing and monitoring'</a>.)</p><p>Issues related to the use of heparin in patients with a prior history of heparin-induced thrombocytopenia (HIT) are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/95336.html" rel="external">"Venous thromboembolism: Initiation of anticoagulation"</a> and  <a class="medical medical_review" href="/d/html/95336.html" rel="external">"Venous thromboembolism: Initiation of anticoagulation", section on 'Heparin-induced thrombocytopenia'</a>.)</p><p>There are no randomized trials comparing different anticoagulants in the prevention of thromboembolism in patients with nephrotic syndrome. Our approach to prophylactic anticoagulation is based upon observational studies in patients with nephrotic syndrome, most of which have examined <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, low-molecular-weight heparin, or <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> [<a href="#rid25">25,33,38,42</a>]. Of note, these studies did not include pregnant women with nephrotic syndrome.</p><p>In a retrospective study of 143 nephrotic patients with minimal change disease, focal segmental glomerulosclerosis, and membranous nephropathy, the choice of anticoagulant was determined by the serum albumin. Patients who had a serum albumin of 2.0 to 3.0 g/dL received <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> (75 mg/day), and those with a serum albumin of less than 2.0 g/dL received low-molecular-weight heparin (<a class="drug drug_general" data-topicid="9407" href="/d/drug information/9407.html" rel="external">enoxaparin</a> at 20 mg subcutaneously once daily) for three months, followed by conversion to <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> (goal international normalized ratio [INR] 1.5 to 2.5) if the nephrotic syndrome persisted [<a href="#rid38">38</a>]. Two patients (1.4 percent) developed venous thromboembolism within the first week of therapy; after the first week, there were no further venous thromboembolism events. One patient developed gastrointestinal bleeding that required hospitalization, and two with occult bleeding underwent elective transfusion.</p><p>There is minimal clinical experience with the newer DOACs. These agents have been used in a few patients with side effects or inadequate therapeutic effects from <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> and if the patient is unwilling to take low-molecular-weight heparin [<a href="#rid39">39,43</a>]. If a DOAC is selected, careful attention to dose adjustments in the presence of kidney function impairment is required and the potential for drug interactions should be considered. (See  <a class="medical medical_review" href="/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"</a>.)</p><p class="headingAnchor" id="H4083700010"><span class="h2">Duration of therapy</span><span class="headingEndMark"> — </span>The optimal duration of prophylactic anticoagulation therapy in patients with nephrotic syndrome is not defined. We continue prophylactic anticoagulation until remission of nephrotic syndrome or when a serum albumin above 3.0 g/dL is achieved, at which time we discontinue anticoagulation therapy if there is no other indication for anticoagulation.</p><p class="headingAnchor" id="H2154018406"><span class="h2">Monitoring during therapy</span><span class="headingEndMark"> — </span>All patients on anticoagulation should be monitored clinically for therapeutic efficacy, bleeding, as well as the development of conditions that affect the half-life of the medications used (eg, kidney failure, pregnancy, weight gain/loss), and adverse effects of the medications (eg, skin necrosis, thrombocytopenia). Laboratory monitoring varies with the long-term anticoagulant used. (See  <a class="medical medical_review" href="/d/html/95395.html" rel="external">"Venous thromboembolism: Anticoagulation after initial management", section on 'Monitoring'</a>.)</p><p>In patients treated with <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, the dose should be adjusted to achieve a goal INR between 1.5 and 2.5 [<a href="#rid38">38</a>]. Patients who develop a deep vein thrombosis (DVT)/pulmonary embolism (PE) despite being on warfarin may be considered for DOAC therapy [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"</a>.)</p><p class="headingAnchor" id="H920527300"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110250.html" rel="external">"Society guideline links: Glomerular disease in adults"</a>.)</p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>– Patients with the nephrotic syndrome are at increased risk for venous thrombosis, particularly deep vein thrombosis and renal vein thrombosis, as well as arterial thrombosis. The risk of thrombosis varies among the causes of nephrotic syndrome and appears to be highest in patients with membranous nephropathy (MN). (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis </strong>– The cause of the hypercoagulable state in patients with nephrotic syndrome is not well understood. A variety of hemostatic abnormalities have been described, including decreased levels of natural anticoagulants such as plasminogen and protein C and S (due to urinary losses); increased platelet activation; hyperfibrinogenemia; inhibition of plasminogen activation; and the presence of high-molecular-weight fibrinogen moieties in the circulation. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention of thromboembolism </strong>– The optimal approach to prophylactic anticoagulation in patients with nephrotic syndrome is not well defined. Our approach is as follows (see <a class="local">'Prevention of thromboembolism'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Assessment of bleeding risk </strong>– In patients with nephrotic syndrome who do not have a contraindication to anticoagulation (<a class="graphic graphic_table graphicRef107527" href="/d/graphic/107527.html" rel="external">table 1</a>), the decision to prescribe prophylactic anticoagulation must be balanced against the risk of anticoagulation-associated bleeding. When the risk of bleeding is unclear, it can be estimated using various prediction models, including the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) risk score or the HAS-BLED bleeding risk score (<a class="calc calc_professional" href="/d/html/94104.html" rel="external">calculator 1</a>). In general, prophylactic anticoagulation should be <strong>avoided</strong> in patients who are considered to be at high risk for bleeding. (See <a class="local">'Assessment of bleeding risk'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with membranous nephropathy </strong>– For nonpregnant patients with MN, we suggest prophylactic anticoagulation to decrease the risk of venous thromboembolism for the following patient groups (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients with a low bleeding risk <strong>and </strong>a serum albumin level &lt;3.0 g/dL</p><p class="bulletIndent3"><span class="glyph">-</span>Patients with a low or intermediate bleeding risk <strong>and </strong>a serum albumin level &lt;2.0 g/dL</p><p></p><p class="bulletIndent2">In nonpregnant patients with MN who have an intermediate bleeding risk <strong>and</strong> a serum albumin level between 2.0 and 2.9 g/dL, there is no consensus regarding the approach to anticoagulation. One contributor to this topic would administer prophylactic antiplatelet therapy with <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> (81 mg once daily). Other contributors would administer prophylactic anticoagulation when the serum albumin is between 2.0 and 2.5 g/dL and would not administer prophylactic anticoagulation or aspirin when the serum albumin is between 2.6 and 2.9 g/dL. (See <a class="local">'Patients with membranous nephropathy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with other causes of nephrotic syndrome </strong>– For nonpregnant patients with a cause of nephrotic syndrome other than MN, a low or intermediate bleeding risk, <strong>and </strong>a serum albumin of &lt;2.0 g/dL, we suggest prophylactic anticoagulation to decrease the risk of venous thromboembolism (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2">In nonpregnant patients with a cause of nephrotic syndrome other than MN who have a low or intermediate bleeding risk <strong>and </strong>a serum albumin level between 2.0 and 2.9 g/dL, there is no consensus regarding the approach to anticoagulation. Some contributors to this topic would administer prophylactic antiplatelet therapy with <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> (81 mg once daily). One contributor would administer low-molecular-weight heparin or <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> in patients with acute severe nephrotic syndrome due to minimal change disease, given the higher risk of venous thromboembolism in such patients. (See <a class="local">'Patients with other causes of nephrotic syndrome'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pregnant patients </strong>– In pregnant patients with nephrotic syndrome, regardless of cause, a low or intermediate bleeding risk, <strong>and </strong>a serum albumin of &lt;2.5 g/dL, we suggest prophylactic anticoagulation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). For pregnant patients with MN, a low bleeding risk, <strong>and </strong>a serum albumin of &lt;3.0 g/dL, we suggest prophylactic anticoagulation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Low-molecular-weight heparin is the preferred anticoagulation strategy in pregnant patients. (See <a class="local">'Pregnant patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Choice of anticoagulant </strong>– In patients selected for anticoagulation, we choose either <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> or low-molecular-weight heparin. We do not routinely prescribe direct oral anticoagulants (DOACs), given the limited data evaluating their use in patients with nephrotic syndrome. However, use of DOACs may be considered in patients with side effects or inadequate therapeutic effects from warfarin and if the patient is unwilling to take low-molecular-weight heparin. Initial dosing and duration of therapy are discussed above. (See <a class="local">'Dosing and efficacy'</a> above and <a class="local">'Duration of therapy'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Llach F. Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome. Kidney Int 1985; 28:429.</a></li><li><a class="nounderline abstract_t">Rabelink TJ, Zwaginga JJ, Koomans HA, Sixma JJ. Thrombosis and hemostasis in renal disease. Kidney Int 1994; 46:287.</a></li><li><a class="nounderline abstract_t">Crew RJ, Radhakrishnan J, Appel G. Complications of the nephrotic syndrome and their treatment. Clin Nephrol 2004; 62:245.</a></li><li><a class="nounderline abstract_t">Singhal R, Brimble KS. Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management. Thromb Res 2006; 118:397.</a></li><li><a class="nounderline abstract_t">Tarry WC, Moser AJ, Makhoul RG. Peripheral arterial thrombosis in the nephrotic syndrome. Surgery 1993; 114:618.</a></li><li><a class="nounderline abstract_t">Parag KB, Somers SR, Seedat YK, et al. Arterial thrombosis in nephrotic syndrome. Am J Kidney Dis 1990; 15:176.</a></li><li><a class="nounderline abstract_t">Mahmoodi BK, ten Kate MK, Waanders F, et al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation 2008; 117:224.</a></li><li><a class="nounderline abstract_t">Vestergaard SV, Birn H, Darvalics B, et al. Risk of Arterial Thromboembolism, Venous Thromboembolism, and Bleeding in Patients with Nephrotic Syndrome: A Population-Based Cohort Study. Am J Med 2022; 135:615.</a></li><li><a class="nounderline abstract_t">Christiansen CF, Schmidt M, Lamberg AL, et al. Kidney disease and risk of venous thromboembolism: a nationwide population-based case-control study. J Thromb Haemost 2014; 12:1449.</a></li><li><a class="nounderline abstract_t">Barbour SJ, Greenwald A, Djurdjev O, et al. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int 2012; 81:190.</a></li><li><a class="nounderline abstract_t">Lionaki S, Derebail VK, Hogan SL, et al. Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol 2012; 7:43.</a></li><li><a class="nounderline abstract_t">Llach F, Papper S, Massry SG. The clinical spectrum of renal vein thrombosis: acute and chronic. Am J Med 1980; 69:819.</a></li><li><a class="nounderline abstract_t">Chugh KS, Malik N, Uberoi HS, et al. Renal vein thrombosis in nephrotic syndrome--a prospective study and review. Postgrad Med J 1981; 57:566.</a></li><li><a class="nounderline abstract_t">Mercadal L, Montcel ST, Nochy D, et al. Factors affecting outcome and prognosis in membranous lupus nephropathy. Nephrol Dial Transplant 2002; 17:1771.</a></li><li><a class="nounderline abstract_t">Maas RJ, Deegens JK, Beukhof JR, et al. The Clinical Course of Minimal Change Nephrotic Syndrome With Onset in Adulthood or Late Adolescence: A Case Series. Am J Kidney Dis 2017; 69:637.</a></li><li><a class="nounderline abstract_t">Fenton A, Smith SW, Hewins P. Adult minimal-change disease: observational data from a UK centre on patient characteristics, therapies, and outcomes. BMC Nephrol 2018; 19:207.</a></li><li><a class="nounderline abstract_t">Cherng SC, Huang WS, Wang YF, et al. The role of lung scintigraphy in the diagnosis of nephrotic syndrome with pulmonary embolism. Clin Nucl Med 2000; 25:167.</a></li><li><a class="nounderline abstract_t">Kuhlmann U, Steurer J, Bollinger A, et al. [Incidence and clinical significance of thromboses and thrombo-embolic complications in nephrotic syndrome patients]. Schweiz Med Wochenschr 1981; 111:1034.</a></li><li><a class="nounderline abstract_t">Waldman M, Crew RJ, Valeri A, et al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol 2007; 2:445.</a></li><li><a class="nounderline abstract_t">Garcia Moreira V, Beridze Vaktangova N, Martinez Gago MD, et al. Overestimation of Albumin Measured by Bromocresol Green vs Bromocresol Purple Method: Influence of Acute-Phase Globulins. Lab Med 2018; 49:355.</a></li><li><a class="nounderline abstract_t">Kayali F, Najjar R, Aswad F, et al. Venous thromboembolism in patients hospitalized with nephrotic syndrome. Am J Med 2008; 121:226.</a></li><li><a class="nounderline abstract_t">Andrassy K, Ritz E, Bommer J. Hypercoagulability in the Nephrotic syndrome. Klin Wochenschr 1980; 58:1029.</a></li><li><a class="nounderline abstract_t">Wagoner RD, Stanson AW, Holley KE, Winter CS. Renal vein thrombosis in idiopathic membranous glomerulopathy and nephrotic syndrome: incidence and significance. Kidney Int 1983; 23:368.</a></li><li><a class="nounderline abstract_t">Velasquez Forero F, Garcia Prugue N, Ruiz Morales N. Idiopathic nephrotic syndrome of the adult with asymptomatic thrombosis of the renal vein. Am J Nephrol 1988; 8:457.</a></li><li><a class="nounderline abstract_t">Sarasin FP, Schifferli JA. Prophylactic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy. Kidney Int 1994; 45:578.</a></li><li><a class="nounderline abstract_t">Chen TY, Huang CC, Tsao CJ. Hemostatic molecular markers in nephrotic syndrome. Am J Hematol 1993; 44:276.</a></li><li><a class="nounderline abstract_t">Loscalzo J. Venous thrombosis in the nephrotic syndrome. N Engl J Med 2013; 368:956.</a></li><li><a class="nounderline abstract_t">Robert A, Olmer M, Sampol J, et al. Clinical correlation between hypercoagulability and thrombo-embolic phenomena. Kidney Int 1987; 31:830.</a></li><li><a class="nounderline abstract_t">Alkjaersig N, Fletcher AP, Narayanan M, Robson AM. Course and resolution of the coagulopathy in nephrotic children. Kidney Int 1987; 31:772.</a></li><li><a class="nounderline abstract_t">Wakui H, Imai H, Komatsuda A, Miura AB. Circulating antibodies against alpha-enolase in patients with primary membranous nephropathy (MN). Clin Exp Immunol 1999; 118:445.</a></li><li><a class="nounderline abstract_t">López-Alemany R, Longstaff C, Hawley S, et al. Inhibition of cell surface mediated plasminogen activation by a monoclonal antibody against alpha-Enolase. Am J Hematol 2003; 72:234.</a></li><li><a class="nounderline abstract_t">Abdelghani E, Waller AP, Wolfgang KJ, et al. Exploring the Role of Antithrombin in Nephrotic Syndrome-Associated Hypercoagulopathy: A Multi-Cohort Study and Meta-Analysis. Clin J Am Soc Nephrol 2023; 18:234.</a></li><li><a class="nounderline abstract_t">Rostoker G, Durand-Zaleski I, Petit-Phar M, et al. Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular-weight heparin enoxaparin. Nephron 1995; 69:20.</a></li><li><a class="nounderline abstract_t">Glassock RJ. Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum. J Am Soc Nephrol 2007; 18:2221.</a></li><li><a class="nounderline abstract_t">Lee T, Biddle AK, Lionaki S, et al. Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy. Kidney Int 2014; 85:1412.</a></li><li><a class="nounderline abstract_t">Lin R, McDonald G, Jolly T, et al. A Systematic Review of Prophylactic Anticoagulation in Nephrotic Syndrome. Kidney Int Rep 2020; 5:435.</a></li><li><a class="nounderline abstract_t">Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011; 58:395.</a></li><li><a class="nounderline abstract_t">Medjeral-Thomas N, Ziaj S, Condon M, et al. Retrospective analysis of a novel regimen for the prevention of venous thromboembolism in nephrotic syndrome. Clin J Am Soc Nephrol 2014; 9:478.</a></li><li><a class="nounderline abstract_t">Sexton DJ, de Freitas DG, Little MA, et al. Direct-Acting Oral Anticoagulants as Prophylaxis Against Thromboembolism in the Nephrotic Syndrome. Kidney Int Rep 2018; 3:784.</a></li><li><a class="nounderline abstract_t">Reynolds ML, Nachman PH, Mooberry MJ, et al. Recurrent venous thromboembolism in primary membranous nephropathy despite direct Xa inhibitor therapy. J Nephrol 2019; 32:669.</a></li><li><a class="nounderline abstract_t">Wei MY, Ward SM. The Anti-Factor Xa Range For Low Molecular Weight Heparin Thromboprophylaxis. Hematol Rep 2015; 7:5844.</a></li><li><a class="nounderline abstract_t">Bellomo R, Atkins RC. Membranous nephropathy and thromboembolism: is prophylactic anticoagulation warranted? Nephron 1993; 63:249.</a></li><li><a class="nounderline abstract_t">Derebail VK, Rheault MN, Kerlin BA. Role of direct oral anticoagulants in patients with kidney disease. Kidney Int 2020; 97:664.</a></li></ol></div><div id="topicVersionRevision">Topic 3043 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3906225" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7967339" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Thrombosis and hemostasis in renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15524054" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Complications of the nephrotic syndrome and their treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15990160" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8367821" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Peripheral arterial thrombosis in the nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2301389" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Arterial thrombosis in nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18158362" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34979093" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Risk of Arterial Thromboembolism, Venous Thromboembolism, and Bleeding in Patients with Nephrotic Syndrome: A Population-Based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25040558" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Kidney disease and risk of venous thromboembolism: a nationwide population-based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21918501" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22076873" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Venous thromboembolism in patients with membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7446547" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The clinical spectrum of renal vein thrombosis: acute and chronic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7329894" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Renal vein thrombosis in nephrotic syndrome--a prospective study and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12270983" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Factors affecting outcome and prognosis in membranous lupus nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28089478" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The Clinical Course of Minimal Change Nephrotic Syndrome With Onset in Adulthood or Late Adolescence: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30115013" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Adult minimal-change disease: observational data from a UK centre on patient characteristics, therapies, and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10698409" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The role of lung scintigraphy in the diagnosis of nephrotic syndrome with pulmonary embolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7268357" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : [Incidence and clinical significance of thromboses and thrombo-embolic complications in nephrotic syndrome patients].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699450" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Adult minimal-change disease: clinical characteristics, treatment, and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29790973" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Overestimation of Albumin Measured by Bromocresol Green vs Bromocresol Purple Method: Influence of Acute-Phase Globulins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18328307" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Venous thromboembolism in patients hospitalized with nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7005524" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Hypercoagulability in the Nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6842962" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Renal vein thrombosis in idiopathic membranous glomerulopathy and nephrotic syndrome: incidence and significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3218659" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Idiopathic nephrotic syndrome of the adult with asymptomatic thrombosis of the renal vein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8164448" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Prophylactic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8238000" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Hemostatic molecular markers in nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23465106" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Venous thrombosis in the nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2437353" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clinical correlation between hypercoagulability and thrombo-embolic phenomena.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2437352" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Course and resolution of the coagulopathy in nephrotic children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10594566" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Circulating antibodies against alpha-enolase in patients with primary membranous nephropathy (MN).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12666133" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Inhibition of cell surface mediated plasminogen activation by a monoclonal antibody against alpha-Enolase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36754010" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Exploring the Role of Antithrombin in Nephrotic Syndrome-Associated Hypercoagulopathy: A Multi-Cohort Study and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7891793" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular-weight heparin enoxaparin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17599972" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24336031" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32274450" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A Systematic Review of Prophylactic Anticoagulation in Nephrotic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21757117" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24334865" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Retrospective analysis of a novel regimen for the prevention of venous thromboembolism in nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29989039" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Direct-Acting Oral Anticoagulants as Prophylaxis Against Thromboembolism in the Nephrotic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30421320" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Recurrent venous thromboembolism in primary membranous nephropathy despite direct Xa inhibitor therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26733269" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The Anti-Factor Xa Range For Low Molecular Weight Heparin Thromboprophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8446259" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Membranous nephropathy and thromboembolism: is prophylactic anticoagulation warranted?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32107019" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Role of direct oral anticoagulants in patients with kidney disease.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
